Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have earned a consensus rating of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $6.1667.

CNTX has been the subject of several analyst reports. D. Boral Capital restated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Tuesday, March 24th. Maxim Group decreased their target price on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Monday, April 20th. Guggenheim restated a “buy” rating and set a $5.00 price objective on shares of Context Therapeutics in a research note on Tuesday, March 24th. Finally, Wall Street Zen cut Context Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 6th.

Context Therapeutics Price Performance

CNTX opened at $0.65 on Monday. Context Therapeutics has a 12 month low of $0.55 and a 12 month high of $3.62. The company has a fifty day simple moving average of $1.77 and a 200 day simple moving average of $2.05. The stock has a market cap of $60.06 million, a P/E ratio of -1.56 and a beta of 1.75.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.03. On average, equities research analysts expect that Context Therapeutics will post -0.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CNTX. Blue Owl Capital Holdings LP grew its stake in Context Therapeutics by 0.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after buying an additional 25,000 shares during the last quarter. Octagon Capital Advisors LP bought a new position in shares of Context Therapeutics during the first quarter worth approximately $13,755,000. Vanguard Group Inc. lifted its holdings in Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares during the last quarter. Millennium Management LLC bought a new stake in Context Therapeutics in the 4th quarter valued at $3,824,000. Finally, Marshall Wace LLP grew its holdings in Context Therapeutics by 7,153.7% in the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after buying an additional 2,557,448 shares in the last quarter. 14.03% of the stock is owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.